STOCKHOLM, May 8, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple System ...
Tiziana's foralumab continues to be safe and well-tolerated, with no drug-related serious side effects after long-term use, ...
DUBLIN, Aug. 25, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), today announced completion of enrollment in the open-label portion of its ...
Please provide your email address to receive an email when new articles are posted on . Relapsing MS patients, as well as those with disability progression independent of relapse activity, experienced ...
Patients typically live about 6 to 10 years after MSA symptoms first appear, with few patients surviving more than 15 years [1],[2]. MSA is significantly debilitating and classified as a rare disease, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback